Pharma BD Deal Intelligence
A $90M bet on needle-free Botox that never reached a patient — quietly written off as R&D expense and forgotten
Full analysis, sources & comparables →EVP David Nicholson said the deal applies Allergan's 'tremendous scientific leadership in neurotoxins' to extend the pipeline with a new delivery system;…
Allergan strengthens its position in the worldwide neuromodulator market, layering ANT-1207 onto a BOTOX franchise that posted $1.3B in 9M 2015 sales; topical…
Allergan acquires Anterios to enhance neurotoxin delivery, bolstering its Botox portfolio through technology that would not require injections for the delivery…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Allergan acquired Anterios, a clinical-stage biopharmaceutical company developing topical botulinum toxin products and proprietary needle-free delivery (NDS) platform. Upfront payment of $90M plus undisclosed development and commercialization milestones. Pre-closing, Anterios spun out certain assets to Eirion Therapeutics.
A $90M bet on needle-free Botox that never reached a patient — quietly written off as R&D expense and forgotten
Assessment window: 10yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Allergan plc / Anterios, Inc. (this deal) | 2016 | $90M | 19 |
| Allergan plc / Merck & Co., Inc. (CGRP receptor antagonist program) | 2015 | $250M | 91 |
| Allergan plc / SkinMedica, Inc. | 2012 | $375M | 55 |
| Allergan plc / Inamed Corporation | 2005 | $3.2B | 50 |
| Allergan plc / Oculeve, Inc. | 2015 | $250M | 33 |
| Allergan plc / Zeltiq Aesthetics, Inc. | 2017 | $2.5B | 32 |
| Allergan plc / Kythera Biopharmaceuticals, Inc. | 2015 | $2.1B | 23 |
← Browse all deals · How we score deals
More: 2016 deals · Allergan plc deals · Dermatology deals